ArticleInternational journal of biological sciences2020
Diagnostic, progressive and prognostic performance of m
Article in International journal of biological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 60 citations in OpenAlex.
- Clinical Significance of RBM15 in Gastric Cancer: A Multi-Database Validation.Current medicinal chemistry · 2026Article
- Mechanism of the N6-methyladenosine reader heterogeneous nuclear ribonucleoprotein C facilitating immune escape in thyroid cancer by stabilizing programmed death ligand 1.Cytotechnology · 2025Article
- Development and validation of nomograms for predicting the prognosis of colorectal cancer patients.Translational cancer research · 2025Article
- Interactions between ALKBH5 and reader proteins in tumors: functions and molecular mechanisms.Frontiers in oncology · 2025Review
- The therapeutic potential of RNA m(6)A in lung cancer.Cell communication and signaling : CCS · 2024Review
- Roles of naïve CD4Journal of translational medicine · 2024Article
- Progression of mCell death discovery · 2024Review
- Article
- Link between m6A modification and infiltration characterization of tumor microenvironment in lung adenocarcinoma.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Bayesian Approaches in Exploring Gene-environment and Gene-gene Interactions: A Comprehensive Review.Cancer genomics & proteomics · 2023Review
- The critical roles of m6A RNA methylation in lung cancer: from mechanism to prognosis and therapy.British journal of cancer · 2023Review
- Identification of a mBMC pulmonary medicine · 2023Article
- Article
- The role of regulators of RNA mGenes & diseases · 2023Review
- A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.Frontiers in immunology · 2023Article
- The role of m6A demethylases in lung cancer: diagnostic and therapeutic implications.Frontiers in immunology · 2023Review
- Emerging role of N6-methyladenosine RNA methylation in lung diseases.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma.Cancer communications (London, England) · 2022Article
- An analysis of the role of HnRNP C dysregulation in cancers.Biomarker research · 2022Review
- Insight into the structure, physiological function, and role in cancer of m6A readers-YTH domain-containing proteins.Cell death discovery · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.